Literature DB >> 26597947

More than the genes, the tumor microenvironment in neuroblastoma.

Lucia Borriello1, Robert C Seeger1, Shahab Asgharzadeh1, Yves A DeClerck2.   

Abstract

Neuroblastoma is the second most common solid tumor in children. Since the seminal discovery of the role of amplification of the MYCN oncogene in the pathogenesis of neuroblastoma in the 1980s, much focus has been on the contribution of genetic alterations in the progression of this cancer. However it is now clear that not only genetic events play a role but that the tumor microenvironment (TME) substantially contributes to the biology of neuroblastoma. In this article, we present a comprehensive review of the literature on the contribution of the TME to the ten hallmarks of cancer in neuroblastoma and discuss the mechanisms of communication between neuroblastoma cells and the TME that underlie the influence of the TME on neuroblastoma progression. We end our review by discussing how the knowledge acquired over the last two decades in this field is now leading to new clinical trials targeting the TME.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cell–cell communication; Hallmarks of cancer; Neuroblastoma; Tumor microenvironment

Mesh:

Substances:

Year:  2015        PMID: 26597947      PMCID: PMC5558454          DOI: 10.1016/j.canlet.2015.11.017

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  150 in total

1.  Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival.

Authors:  S G DuBois; Y Kalika; J N Lukens; G M Brodeur; R C Seeger; J B Atkinson; G M Haase; C T Black; C Perez; H Shimada; R Gerbing; D O Stram; K K Matthay
Journal:  J Pediatr Hematol Oncol       Date:  1999 May-Jun       Impact factor: 1.289

Review 2.  Bone marrow mesenchymal stem cells and TGF-β signaling in bone remodeling.

Authors:  Janet L Crane; Xu Cao
Journal:  J Clin Invest       Date:  2014-02-03       Impact factor: 14.808

3.  Insulin-like growth factor I stimulates motility in human neuroblastoma cells.

Authors:  G E Meyer; E Shelden; B Kim; E L Feldman
Journal:  Oncogene       Date:  2001-11-08       Impact factor: 9.867

4.  Identification of galectin-3-binding protein as a factor secreted by tumor cells that stimulates interleukin-6 expression in the bone marrow stroma.

Authors:  Yasushi Fukaya; Hiroyuki Shimada; Ling-Chi Wang; Ebrahim Zandi; Yves A DeClerck
Journal:  J Biol Chem       Date:  2008-05-01       Impact factor: 5.157

5.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

Authors:  G M Brodeur; R C Seeger; M Schwab; H E Varmus; J M Bishop
Journal:  Science       Date:  1984-06-08       Impact factor: 47.728

6.  N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma.

Authors:  J Kang; P G Rychahou; T A Ishola; J M Mourot; B M Evers; D H Chung
Journal:  Oncogene       Date:  2008-02-18       Impact factor: 9.867

7.  Schwann cell-conditioned medium promotes neuroblastoma survival and differentiation.

Authors:  J L Kwiatkowski; J L Rutkowski; D J Yamashiro; G I Tennekoon; G M Brodeur
Journal:  Cancer Res       Date:  1998-10-15       Impact factor: 12.701

8.  Insulin-like growth factor-I signaling in human neuroblastoma cells.

Authors:  Bhumsoo Kim; Cynthia M van Golen; Eva L Feldman
Journal:  Oncogene       Date:  2004-01-08       Impact factor: 9.867

9.  Proteome profiling of neuroblastoma-derived exosomes reveal the expression of proteins potentially involved in tumor progression.

Authors:  Danilo Marimpietri; Andrea Petretto; Lizzia Raffaghello; Annalisa Pezzolo; Cristina Gagliani; Carlo Tacchetti; Pierluigi Mauri; Giovanni Melioli; Vito Pistoia
Journal:  PLoS One       Date:  2013-09-19       Impact factor: 3.240

Review 10.  Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches.

Authors:  Cristina Bottino; Alessandra Dondero; Francesca Bellora; Lorenzo Moretta; Franco Locatelli; Vito Pistoia; Alessandro Moretta; Roberta Castriconi
Journal:  Front Immunol       Date:  2014-02-12       Impact factor: 7.561

View more
  33 in total

1.  Differences in Genomic Profiles and Outcomes Between Thoracic and Adrenal Neuroblastoma.

Authors:  Derek A Oldridge; Bao Truong; Douglas Russ; Steven G DuBois; Zalman Vaksman; Yael P Mosse; Sharon J Diskin; John M Maris; Katherine K Matthay
Journal:  J Natl Cancer Inst       Date:  2019-11-01       Impact factor: 13.506

2.  Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells.

Authors:  Lucia Borriello; Rie Nakata; Michael A Sheard; G Esteban Fernandez; Richard Sposto; Jemily Malvar; Laurence Blavier; Hiroyuki Shimada; Shahab Asgharzadeh; Robert C Seeger; Yves A DeClerck
Journal:  Cancer Res       Date:  2017-07-07       Impact factor: 12.701

3.  Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.

Authors:  Rajen Mody; Arlene Naranjo; Collin Van Ryn; Alice L Yu; Wendy B London; Barry L Shulkin; Marguerite T Parisi; Sabah-E-Noor Servaes; Mitchell B Diccianni; Paul M Sondel; Julia G Bender; John M Maris; Julie R Park; Rochelle Bagatell
Journal:  Lancet Oncol       Date:  2017-05-23       Impact factor: 41.316

Review 4.  The emerging roles of macrophages in cancer metastasis and response to chemotherapy.

Authors:  Luis Rivera Sanchez; Lucia Borriello; David Entenberg; John S Condeelis; Maja H Oktay; George S Karagiannis
Journal:  J Leukoc Biol       Date:  2019-02-05       Impact factor: 4.962

5.  Comparison of the uptake of untargeted and targeted immunostimulatory nanoparticles by immune cells in the microenvironment of metastatic breast cancer.

Authors:  Gil Covarrubias; Taylor J Moon; Georgia Loutrianakis; Haley M Sims; Mayura P Umapathy; Morgan E Lorkowski; Peter A Bielecki; Michelle L Wiese; Prabhani U Atukorale; Efstathios Karathanasis
Journal:  J Mater Chem B       Date:  2022-01-05       Impact factor: 6.331

6.  An Engineered Prussian Blue Nanoparticles-based Nanoimmunotherapy Elicits Robust and Persistent Immunological Memory in a TH-MYCN Neuroblastoma Model.

Authors:  Anshi Shukla; Juliana Cano-Mejia; Jaclyn Andricovich; Rachel A Burga; Elizabeth E Sweeney; Rohan Fernandes
Journal:  Adv Nanobiomed Res       Date:  2021-03-13

Review 7.  The application of tumor cell-derived vesicles in oncology therapy.

Authors:  Ximei Xu; Yin Xiang; Yang Yang; Kai Liu; Zhiwei Cui; Xiaodong Tong; Junliang Chen; Fang Hou; Zhiqiang Luo
Journal:  Clin Transl Oncol       Date:  2022-10-07       Impact factor: 3.340

8.  Verification of genetic differences and immune cell infiltration subtypes in the neuroblastoma tumour microenvironment during immunotherapy.

Authors:  Bo Qian; Jing Sun; Pengcheng Zuo; Min Da; Xuming Mo; Yongjun Fang
Journal:  World J Surg Oncol       Date:  2022-05-28       Impact factor: 3.253

9.  The role of the tumor microenvironment in tumor cell intravasation and dissemination.

Authors:  Lucia Borriello; George S Karagiannis; Camille L Duran; Anouchka Coste; Maja H Oktay; David Entenberg; John S Condeelis
Journal:  Eur J Cell Biol       Date:  2020-07-02       Impact factor: 4.492

10.  Serine-Threonine Kinase Receptor-Associated Protein (STRAP) Knockout Decreases the Malignant Phenotype in Neuroblastoma Cell Lines.

Authors:  Laura V Bownes; Adele P Williams; Raoud Marayati; Colin H Quinn; Sara C Hutchins; Jerry E Stewart; Trung Vu; Juliet L Easlick; Elizabeth Mroczek-Musulman; David K Crossman; Joshua C Anderson; Christopher D Willey; Pran K Datta; Elizabeth A Beierle
Journal:  Cancers (Basel)       Date:  2021-06-26       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.